IQE
plc
Cardiff, UK
10 September 2024
Unaudited Results for the
six months ended 30 June 2024
Steady progress with
year-on-year revenue growth
IQE plc (AIM: IQE, "IQE" or
the "Group"), the leading global supplier
of compound semiconductor wafer products and advanced material
solutions, announces its interim
results for the
six months ended 30 June 2024. Revenue for
the period was £66.0m, with an adjusted non-GAAP EBITDA of
£6.6m.
Americo Lemos, Chief Executive Officer of IQE,
commented:
"IQE delivered a consistent performance in the first half of
2024, with a 27% rise in revenue year-on-year and a return to a
positive adjusted EBITDA position. We expect the market to continue
to show pockets of recovery during the second half, resulting in
more moderate growth for 2024 on a full-year basis.
We look forward
to progressing the planned IPO of our Taiwanese subsidiary, which
will help to accelerate our diversification strategy into the GaN
Power market and microLED, and will provide additional significant
cash resources for the Company."
H1 2024 Financial Results
|
H1 2024
£'m*
|
H1 2023
£'m*
|
|
|
|
Revenue
|
66.0
|
52.0
|
Adjusted EBITDA**
|
6.6
|
(5.7)
|
Operating loss
|
(12.1)
|
(19.6)
|
Adjusted operating
loss**
|
(7.2)
|
(17.5)
|
Reported loss after tax
|
(15.1)
|
(21.3)
|
Diluted EPS
|
(1.57p)
|
(2.57p)
|
Adjusted diluted EPS**
|
(1.05p)
|
(2.30p)
|
Cash generated from
operations
|
(2.6)
|
2.4
|
Adjusted cash from
operations**
|
1.8
|
4.3
|
Capital Investment
(PP&E)
|
5.0
|
5.2
|
Net funds / (debt)***
|
(17.0)
|
5.3
|
* All figures £'m excluding diluted and adjusted
diluted EPS.
** Adjusted Measures: Alternative performance measures are
disclosed separately after a number of non-cash charges,
non-operational items and significant infrequent items that would
distort period on period comparability. Adjusted items are
material items of income or expense that have been shown separately
due to the significance of their nature or amount
as detailed in
note 8.
*** Net funds/debt excludes IFRS16 lease liabilities and fair
value gains/losses on derivative instruments.
The following highlights of the first half results are based
on these adjusted performance measures, unless otherwise
stated.
Strategic Highlights
Wireless
Growth driven by communications infrastructure and
penetration into the Android smartphone and WiFi
market
· Successful
launch of an 8" GaN on Si product with a major Tier 1 foundry
supporting 5G RF base station infrastructure.
· Delivered high
power RF amplifier products using GaN on SiC for 5G base station
radios to both IDM and fabless customers in North America, Europe
and Asia.
· Delivered sample
GaAs HBT power amplifiers to two leading compound semiconductor
foundries, enabling 5G RF Front End products for Android
smartphones and WiFi 7.
Photonics
Well positioned with new technology to capture demand from
Gen AI data centres
· Qualification of
InP laser technology for high-speed optical transceivers deployed
within large-scale gen AI data centres.
· Delivery of new
high speed data communications VCSEL product to address market
demand for short-reach optical transceiver applications.
· Qualification of
Quantum Dot Laser (QDL) products by an industry-leading Silicon
Photonics customer, enabling the development of energy-efficient,
on-chip laser architectures for next-generation data centre
networking applications.
·
Delivery of next-generation 3D Sensing VCSEL
products for module-level qualification in new AR/VR and mobile
platforms.
Power
Increased GaN capacity enabling qualification
ramp-up
· Progress with
customer qualification of 650V e/d-mode GaN products for Tier 1
OEMs.
· Continued to
deploy GaN Power capacity in the US and UK to serve the global
Power Electronics market
Display
Successful development driving sampling with new and existing
customers
· Successful
launch of new 8" GaAs and GaN RGB microLED product portfolio with
strong engagement from Tier 1 consumer mobile and display
manufacturers.
· Continuation of
long term engagement with an AR/VR customer to deliver
next-generation microLED display materials.
H1 2024 Financial Highlights
· Revenue
of £66.0m (H1 2023: £52.0m) increased 26.9% vs H1
2023.
‒ Wireless
revenue of £38.8m (H1 2023: £22.4m) increased 73%
year-on-year on a reported basis. This was a result of inventory
normalisation and design wins in Android RF Front End
markets.
‒ Photonics
revenue of £26.8m (H1 2023: £28.0m) was down 4%
year-on-year on a reported basis. A reduction in segments of InP
telecoms markets was partially offset by strength in GaAs Photonics
and infrared sensing product sales.
‒ CMOS++
revenue of £0.5m (H1 2023: £1.6m) down 70% on a
reported basis. This reflects a strategic rebalancing of IQE's
product portfolio and a shift in focus towards diversification into
GaN Power and MicroLED. Reporting on this segment will cease from
2025.
· Adjusted
EBITDA of £6.6m (H1 2023: £(5.7)m
LBITDA) up £12.3m, as a result of a combination of increased
revenue, improved asset utilisation, and the benefit of cost
control actions.
· Reported operating
loss of £(12.1)m (H1 2023: £(19.6)m
loss).
· Adjusted cash
inflow from operations of £1.8m (H1
2023: £4.3m) reflecting a combination of improved trading
performance offset by an increase in working capital.
· Total net cash capex and
cash investment in intangibles of
£6.5m (H1 2023: £8.4m)
·
Adjusted net
debt of £(17.0)m as at 30 June 2024
(net debt of £(2.2)m as at 31 Dec 2023, net funds of £5.3m as at 30
June 2023).
·
Cost control
actions
‒ Reduced labour costs by c.10% year-on-year while ensuring
balance of operational efficiency and skills retention.
‒ Reduced non-labour costs by c.5% year-on-year.
‒ Sale of decommissioned Pennsylvania site expected to complete
in H2 2024.
Current trading and outlook
Signs of recovery in the global
semiconductor industry continue, despite the pace of progress
varying between regions and market segments.
IQE delivered an improved
performance in H1 and year-on-year growth is expected in both
revenue and adjusted EBITDA for FY 2024. With some markets
remaining in recovery in H2 2024, performance is expected to be at
the lower end of the range of analyst forecasts for the full
year1.
IQE will maintain a tight focus on
structural cost controls, footprint optimisation and operational
efficiencies. This will allow the business to continue to improve
its profitability while building its market-led technology roadmap
in partnership with key customers.
In July 2024, the Group announced
plans for the IPO of its Taiwan operating subsidiary on the Taiwan
Stock Exchange. This represents an exciting opportunity for IQE to
maximise value across its asset base and accelerate the investment
in its growth and diversification strategy while continuing to
maintain its secure and resilient supply chain. The Group has had a
very positive reaction from its first round of engagement with
investors in the region, and expects to list on the Emerging Market
Board of the Taiwan Stock Exchange in H1 2025. Further updates will
be provided when appropriate.
1. The analyst range of expectations for FY 2024 revenue are
from £130.0m to £153.7m and for adjusted EBITDA from £11.1m to
£16.6m.
Results Presentation
IQE will present its H1 2024
Results via webcast at 9:00am today, Tuesday 10 September 2024. If
you would like to view this webcast, please register by using the
below link and following the instructions:
https://brrmedia.news/IQE_IR_24
Contacts:
IQE plc
+44 (0) 29 2083 9400
Americo Lemos
Jutta Meier
Amy Barlow
Peel Hunt (Nomad and Joint Broker)
+44 (0) 20 7418 8900
Ben Cryer
Kate Bannatyne
Adam Telling
Deutsche Numis (Joint Broker)
+44 (0) 20 7260 1000
Simon Willis
Hugo Rubinstein
Iqra Amin
Headland Consultancy (Financial PR)
+ 44 (0) 20
38054822
Andy Rivett-Carnac: +44 (0) 7968
997 365
Chloe Francklin: +44 (0)78 3497
4624
ABOUT IQE
http://iqep.com
IQE is the leading global supplier
of advanced compound semiconductor wafers and materials solutions
that enable a diverse range of applications across:
·
Smart Connected Devices
·
Communications Infrastructure
·
Automotive and Industrial
·
Aerospace and Security
As a scaled global epitaxy wafer
manufacturer, IQE is uniquely positioned in this market which has
high barriers to entry. IQE supplies the global market and is
enabling customers to innovate at chip and OEM level. By leveraging
the Group's intellectual property portfolio including know-how and
patents, it produces epitaxy wafers of superior quality, yield and
unit economics.
IQE is headquartered in Cardiff UK, with employees across
manufacturing locations in the UK, US and Taiwan, and is listed on
the AIM Stock Exchange in London.
Financial
Review
Consolidated Income Statement
|
|
|
|
|
|
6 months
to
|
6 months
to
|
12 months
to
|
|
30 Jun
2024
|
30 Jun
2023
|
31 Dec
2023
|
(All figures £'000s)
|
Note
|
Unaudited
|
Unaudited
|
Audited
|
Revenue
|
7
|
66,018
|
52,016
|
115,252
|
Cost of sales
|
|
(61,026)
|
(56,241)
|
(112,924)
|
Gross profit/(loss)
|
|
4,992
|
(4,225)
|
2,328
|
Selling, general and
administrative expenses
|
|
(16,301)
|
(16,404)
|
(32,486)
|
Impairment (loss)/reversal on
trade receivables and contract assets
|
|
(31)
|
355
|
1,808
|
Gain on acquisition of remaining
interest in CSC
|
|
-
|
-
|
2,419
|
(Loss)/profit on disposal of
intangible assets and property, plant and equipment
|
|
(1,094)
|
-
|
152
|
Gains on remeasurement of right of
use asset
|
|
296
|
-
|
-
|
Other gains
|
|
-
|
640
|
-
|
Operating loss
|
7
|
(12,138)
|
(19,634)
|
(25,779)
|
Finance costs
|
|
(1,765)
|
(1,832)
|
(3,032)
|
Adjusted loss before income tax
|
|
(8,972)
|
(19,291)
|
(23,231)
|
Adjustments
|
8
|
(4,931)
|
(2,175)
|
(5,580)
|
Loss before income tax
|
7
|
(13,903)
|
(21,466)
|
(28,811)
|
Taxation
|
|
(1,168)
|
141
|
(567)
|
Loss for the period
|
(15,071)
|
(21,325)
|
(29,378)
|
Loss attributable to:
|
|
|
|
Equity shareholders
|
(15,071)
|
(21,325)
|
(29,378)
|
|
(15,071)
|
(21,325)
|
(29,378)
|
|
|
|
|
Loss per share attributable to owners of the parent during
the period
|
|
|
|
Basic loss per
share
10
|
(1.57p)
|
(2.57p)
|
(3.28p)
|
Diluted loss per
share
10
|
(1.57p)
|
(2.57p)
|
(3.28p)
|
|
|
|
|
|
|
|
|
|
|
Adjusted basic and diluted
earnings per share are presented in Note 10.
All items included in the loss for
the period relate to continuing operations.
Consolidated statement of comprehensive
income
|
|
|
|
6 months
to
|
6 months
to
|
12 months
to
|
|
30 Jun
2024
|
30 Jun
2023
|
31 Dec
2023
|
(All figures £'000s)
|
Unaudited
|
Unaudited
|
Audited
|
Loss for the period
|
(15,071)
|
(21,325)
|
(29,378)
|
Exchange differences on
translation of foreign operations*
|
(1,181)
|
(7,682)
|
(8,088)
|
Total comprehensive expense for the period
|
(16,252)
|
(29,007)
|
(37,466)
|
Total comprehensive expense
attributable to:
|
|
|
|
Equity shareholders
|
(16,252)
|
(29,007)
|
(37,466)
|
|
(16,252)
|
(29,007)
|
(37,466)
|
* Balance might subsequently
be reclassified to the income statement when it becomes
realised.
Consolidated Balance Sheet
|
|
As At
|
As At
|
As At
|
|
|
30 Jun
2024
|
30 Jun
2023
|
31 Dec
2023
|
(All figures £'000s)
|
Note
|
Unaudited
|
Unaudited
|
Audited
|
|
|
|
|
|
Non-current assets
|
|
|
|
|
Intangible assets
|
|
34,275
|
35,061
|
35,378
|
Property, plant and
equipment
|
|
124,716
|
121,640
|
129,553
|
Right of use assets
|
|
45,684
|
38,918
|
37,895
|
Total non-current assets
|
|
204,675
|
195,619
|
202,826
|
|
|
|
|
|
Current assets
|
|
|
|
|
Inventories
|
|
24,618
|
25,874
|
24,577
|
Trade and other
receivables
|
|
46,849
|
36,996
|
38,220
|
Derivative financial
instruments
|
12
|
-
|
259
|
-
|
Cash and cash
equivalents
|
12
|
7,810
|
12,314
|
5,617
|
Assets held for resale
|
|
2,304
|
-
|
2,274
|
Total current assets
|
|
81,581
|
75,443
|
70,688
|
Total assets
|
|
286,256
|
271,062
|
273,514
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
Trade and other
payables
|
|
(48,794)
|
(33,458)
|
(42,572)
|
Current tax liabilities
|
|
(586)
|
(65)
|
(531)
|
Bank borrowings
|
12
|
(1,569)
|
(6,123)
|
(4,153)
|
Lease liabilities
|
12
|
(7,329)
|
(7,140)
|
(5,865)
|
Provisions for other liabilities
and charges
|
|
(1,225)
|
(2,194)
|
(2,998)
|
Total current liabilities
|
|
(59,503)
|
(48,980)
|
(56,119)
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
Trade and other
payables
|
|
(2,148)
|
-
|
(2,208)
|
Bank borrowings
|
12
|
(23,220)
|
(845)
|
(3,692)
|
Lease liabilities
|
12
|
(44,493)
|
(42,826)
|
(40,435)
|
Provisions for other liabilities
and charges
|
|
(504)
|
(1,291)
|
(671)
|
Deferred tax
liabilities
|
|
(710)
|
(710)
|
(604)
|
Total non-current liabilities
|
|
(71,075)
|
(45,672)
|
(47,610)
|
Total liabilities
|
|
(130,578)
|
(94,652)
|
(103,729)
|
Net assets
|
|
155,678
|
176,410
|
169,785
|
Equity attributable to shareholders of the
parent
|
|
|
|
|
Share capital
|
13
|
9,666
|
9,614
|
9,615
|
Share premium
|
|
155,920
|
155,825
|
155,844
|
Retained earnings
|
|
(62,537)
|
(39,413)
|
(47,466)
|
Exchange rate reserve
|
|
31,266
|
32,853
|
32,447
|
Other reserves
|
|
21,363
|
17,531
|
19,345
|
Total equity
|
|
155,678
|
176,410
|
169,785
|
Consolidated Statement of Changes in Equity
|
|
|
|
|
|
|
Unaudited
(All figures £'000s)
|
Share
capital
|
Share
premium
|
Retained
earnings
|
Exchange rate
reserve
|
Other
reserves
|
Total
equity
|
|
|
|
|
|
|
|
At
1 January 2024
|
9,615
|
155,844
|
(47,466)
|
32,447
|
19,345
|
169,785
|
|
|
|
|
|
|
|
Loss for the period
|
-
|
-
|
(15,071)
|
-
|
-
|
(15,071)
|
Other comprehensive expense for the
period
|
-
|
-
|
-
|
(1,181)
|
-
|
(1,181)
|
Total comprehensive expense
|
-
|
-
|
(15,071)
|
(1,181)
|
-
|
(16,252)
|
|
|
|
|
|
|
|
Share based payments
|
-
|
-
|
-
|
-
|
2,018
|
2,018
|
Proceeds from shares issued (net of
expenses)
|
51
|
76
|
-
|
-
|
-
|
127
|
Total transactions with owners
|
51
|
76
|
-
|
-
|
2,018
|
2,145
|
|
|
|
|
|
|
|
At
30 June 2024
|
9,666
|
155,920
|
(62,537)
|
31,266
|
21,363
|
155,678
|
|
|
|
|
|
|
|
Unaudited
(All figures £'000s)
|
Share
capital
|
Share
premium
|
Retained
earnings
|
Exchange rate
reserve
|
Other
reserves
|
Total
equity
|
|
|
|
|
|
|
|
At
1 January 2023
|
8,048
|
154,720
|
(45,246)
|
40,535
|
17,003
|
175,060
|
|
|
|
|
|
|
|
Loss for the period
|
-
|
-
|
(21,325)
|
-
|
-
|
(21,325)
|
Other comprehensive income for the
period
|
-
|
-
|
-
|
(7,682)
|
-
|
(7,682)
|
Total comprehensive expense
|
-
|
-
|
(21,325)
|
(7,682)
|
-
|
(29,007)
|
|
|
|
|
|
|
|
Share based payments
|
-
|
-
|
-
|
-
|
528
|
528
|
Proceeds/charge from shares
issued
|
1,566
|
1,105
|
(1,342)
|
-
|
28,500
|
29,829
|
Transfer of merger reserve to
retained earnings
|
-
|
-
|
28,500
|
-
|
(28,500)
|
-
|
Total transactions with owners
|
1,566
|
1,105
|
27,158
|
-
|
528
|
30,357
|
|
|
|
|
|
|
|
At
30 June 2023
|
9,614
|
155,825
|
(39,413)
|
32,853
|
17,531
|
176,410
|
|
|
|
|
|
|
|
Audited
(All figures £'000s)
|
Share
capital
|
Share
premium
|
Retained
earnings
|
Exchange rate
reserve
|
Other
reserves
|
Total
equity
|
|
|
|
|
|
|
|
At
1 January 2023
|
8,048
|
154,720
|
(45,246)
|
40,535
|
17,003
|
175,060
|
|
|
|
|
|
|
|
Loss for the year
|
-
|
-
|
(29,378)
|
-
|
-
|
(29,378)
|
Other comprehensive expense for the
year
|
-
|
-
|
-
|
(8,088)
|
-
|
(8,088)
|
Total comprehensive expense
|
-
|
-
|
(29,378)
|
(8,088)
|
-
|
(37,466)
|
|
|
|
|
|
|
|
Share based payments
|
-
|
-
|
-
|
-
|
2,484
|
2,484
|
Tax relating to share
options
|
-
|
-
|
-
|
-
|
(142)
|
(142)
|
Proceeds/(charge) from shares
issued
|
1,567
|
1,124
|
(1,342)
|
-
|
28,500
|
29,849
|
Transfer of merger reserve to
retained earnings
|
-
|
-
|
28,500
|
-
|
(28,500)
|
-
|
Total transactions with owners
|
1,567
|
1,124
|
27,158
|
-
|
2,342
|
32,191
|
|
|
|
|
|
|
|
At
31 December 2023
|
9,615
|
155,844
|
(47,466)
|
32,447
|
19,345
|
169,785
|
|
|
|
|
|
|
|
|
|
|
|
| |
The comparative financial
information for the 6 months to 30 June 2023 has been restated to
reclassify £1,342,000 from transfer of merger reserve to retained
earnings to proceeds/(charge) from shares issued in order to adopt
a consistent presentation with the audited financial statements for
the year ended 31 December 2023. The reclassification has had no
impact on net assets, cash flows or loss after tax for the 6 months
to 30 June 2023.
Consolidated Cash Flow Statement
|
|
6 months
to
|
6 months
to
|
12 months
to
|
|
|
30 Jun
2024
|
30 Jun
2023
|
31 Dec
2023
|
|
(All figures £'000s)
|
Note
|
Unaudited
|
Unaudited
|
Audited
|
|
|
|
|
|
|
|
Cash flows from operating activities
|
|
|
|
|
|
Adjusted cash inflow from operations
|
|
1,789
|
4,296
|
15,744
|
|
Cash impact of
adjustments
|
8
|
(4,421)
|
(1,864)
|
(5,670)
|
|
Cash generated from operations
|
11
|
(2,632)
|
2,432
|
10,074
|
|
Net interest paid
|
|
(1,410)
|
(1,565)
|
(3,242)
|
|
Income tax paid
|
|
(701)
|
(726)
|
(912)
|
|
Net cash generated from operating
activities
|
(4,743)
|
141
|
5,920
|
|
|
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
|
|
Purchase of property, plant and
equipment
|
(4,959)
|
(5,183)
|
(12,158)
|
|
Purchase of intangible
assets
|
(916)
|
(1,681)
|
(3,113)
|
|
Capitalised development
expenditure
|
(1,405)
|
(1,590)
|
(2,852)
|
|
Proceeds from disposal of
property, plant and equipment and intangible assets
|
942
|
12
|
553
|
|
Acquisition of subsidiary, net of
cash received
|
(128)
|
-
|
(390)
|
|
Adjusted cash used in investing activities
|
(7,317)
|
(8,442)
|
(17,960)
|
|
Cash impact of adjustments -
proceeds from disposal of property, plant and equipment and
intangible assets
|
8
|
851
|
-
|
-
|
|
Net cash used in investing activities
|
|
(6,466)
|
(8,442)
|
(17,960)
|
|
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
|
|
Proceeds from issuance of ordinary
shares
|
|
127
|
31,219
|
31,239
|
|
Expenses associated with issue of
ordinary shares
|
|
-
|
(1,390)
|
(1,390)
|
|
Proceeds from
borrowings
|
|
19,493
|
5,833
|
9,932
|
|
Repayment of borrowings
|
|
(2,532)
|
(25,302)
|
(28,363)
|
|
Payment of lease
liabilities
|
|
(3,613)
|
(748)
|
(4,787)
|
|
Net cash generated from financing
activities
|
13,475
|
9,612
|
6,631
|
|
Net increase / (decrease) in cash and cash
equivalents
|
2,266
|
1,311
|
(5,409)
|
|
Cash and cash equivalents at the
beginning of the period
|
5,617
|
11,620
|
11,620
|
|
Exchange losses on cash and cash
equivalents
|
|
(73)
|
(617)
|
(594)
|
|
Cash and cash equivalents at the end of the
period
|
12
|
7,810
|
12,314
|
5,617
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
1. REPORTING ENTITY
IQE plc is a public limited
company incorporated in the United Kingdom under the Companies Act
2006. The Company is domiciled in the United Kingdom and is quoted
on the Alternative Investment Market (AIM).
These condensed consolidated
interim financial statements ('interim financial statements') as at
and for the six months ended 30 June 2024 comprise the Company and
its Subsidiaries (together referred to as 'the Group'). The
principal activities of the Group are the development, manufacture
and sale of advanced semiconductor materials.
2. BASIS OF
PREPARATION
These interim financial statements
have been prepared in accordance with IAS 34 'Interim Financial
Reporting', and should be read in conjunction with the Group's last
annual consolidated financial statements as at and for the year
ended 31 December 2023 which were approved
by the Board of Directors on 9 April 2024 and have been delivered
to the Registrar of Companies. The report of the auditors on those
financial statements was unqualified, did not contain an emphasis
of matter paragraph and did not contain any statement under section
498 of the Companies Act 2006.
The interim financial
statements do not include all of the
information required for a complete set of IFRS financial
statements and do not constitute statutory
accounts within the meaning of section 434 of the Companies Act
2006. However, selected explanatory notes are included to explain
events and transactions that are significant to an understanding of
the changes in the Group's financial position and performance since
the last annual financial statements.
Comparative information in the
interim financial statements as at and for the year ended 31
December 2023 has been taken from the published audited financial
statements as at and for the year ended 31 December 2023. All other
periods presented are unaudited.
The Board of Directors and the
Audit Committee approved the interim financial statements on 9
September 2024.
3. GOING CONCERN
The Group experienced weaker
customer demand and lower customer orders in 2023 as a result of
the global semiconductor industry downturn prior to a gradual
improvement in market dynamics and customer demand from Q4 2023
which has delivered revenue growth of 26.9% in H1 2024. Despite the
gradual improvement in market dynamics in H1 2024 the semiconductor
industry remains in recovery as markets continue to correct at
varying paces with slower growth now expected to extend throughout
H2 2024, ahead of an expected full market recovery in
2025.
In the six months to 30 June 2024,
reported revenue increased 26.9% with the group reducing its loss
for the period to £15,071,000 (H1 2023:
£21,325,000, FY23: £29,378,000). The cash
impact of the loss for the period, combined with an increase in
working capital, investment in capital and intangible asset
development and debt and lease service costs has resulted in an
increase in the Group's net debt position (excluding lease
liabilities and fair value gains/losses on derivative instruments)
to £16,979,000 (H1
2022: £5,346,000 net funds, FY23: £2,228,000 net debt). At 30
June 2024 the Group had undrawn committed funding of
£4,300,000 ($5,500,000)
available under the terms of its credit facilities.
In assessing the going concern
basis of preparation the Directors have reviewed financial
projections to 31 December 2025 ('the going concern assessment
period'), containing both a 'base case' and a 'severe but plausible
downside case'. The review period extends beyond the minimum
required 12-month period from the date of approval of the interim
financial statements to protect against the recovery in the
semiconductor market occurring later than forecast by the
Directors.
Base Case
The base case is the Group's latest
Board approved 2024 and 2025 forecasts. The base case incorporates
a gradual improvement in market dynamics in H2 2024 prior to a full
market recovery in 2025 and the impact of cost cutting actions
primarily implemented by the Board in 2023.
In the base case the Group is
forecast to maintain liquidity headroom and to comply with its
leverage and interest cover banking covenants throughout the going
concern assessment period. Liquidity headroom falls to
£5.5m in September 2024 prior to a
gradual forecast improvement during 2025, interest cover as well as
leverage covenant headroom is low at Q4 2024 before a gradual
forecast increase in headroom during 2025 for both
covenants.
Severe but plausible downside case
A severe but plausible downside
scenario was modelled for H2 2024 and 2025, reflecting a
combination of greater uncertainty further out into the future, a
delay in market recovery and a delay in the new Power GaN business
which is forecast to ramp up in 2025. In line with an assumed
revenue reduction in both years, there is a reflective reduction in
variable operating costs for 2024 and 2025, as well as mitigations
in the form of further structural cost savings, and deferred
investment in capital expenditure and technology asset development
over and above those already reflected in the base case. These cost
savings and cash management actions have already been identified,
are in the control of management and are immediately
actionable.
In the severe but plausible
downside scenario modelled, the Group is forecast to maintain
liquidity headroom and to comply with its leverage and interest
cover banking covenants throughout the going concern assessment
period. Liquidity headroom falls to a low of £4.1m in August 2025,
interest cover as well as leverage covenant headroom is low at Q4
2024 before a gradual forecast increase in headroom during 2025 for
both covenants.
Whilst acknowledging that under the
severe but plausible scenario liquidity and covenant headroom is
tight, the Directors believe that the Company and Group will have
adequate cash resources to continue operating for the foreseeable
future and to meet their liabilities as they fall due for the going
concern assessment period, such that the Directors consider it
appropriate to adopt the going concern basis of accounting in
preparing the Company and Group consolidated financial
statements.
4. USE OF JUDGEMENTS AND
ESTIMATES
In preparing these interim
financial statements, management has made judgements and estimates
that affect the application of accounting policies and the reported
amounts of assets, liabilities, income and expense. Actual results
may differ from these estimates.
The significant judgements made by
management in applying the Group's accounting policies and the key
sources of estimation uncertainty were the same as those described
in the last annual financial statements except as
follows:
Impairment of Cash Generating Units ('CGU')
At the end of each reporting
period, the Group assesses whether there is any indication of
impairment of non-current assets allocated to the Group's CGU's.
Multiple production facilities and production assets are included
in a single CGU reflecting that production can (and is) transferred
between sites and production assets for different operating
segments to suit capacity planning and operational efficiency.
Given the interdependency of facilities and production assets
non-current assets are tested for impairment by grouping
operational sites and production assets into CGUs based on type of
production.
In the six months to 30 June 2024,
the Group has experienced a gradual improvement in market dynamics
and customer demand following the global semiconductor industry
downturn, which, combined with a reduction in central corporate
costs has resulted in a reduction in the loss for the period to
£15,071,000 (H1 2023: £21,325,000, 2023:
£29,378,000). The gradual improvement in market dynamics and
customer demand has principally been focused in the Group's
Wireless CGU which has delivered an operating profit of £3,995,000
(H1 2023: £3,262,000 loss, 2023: £3,634,000 profit). The Group's
Photonics CGU continues to be loss making with an operating loss
for the period of £7,495,000 (H1: 2023: £7,179,000, 2023:
£12,433,000). The losses generated within the Photonics CGU and the
low levels of profitability within the Group's Wireless CGU have
been assessed as an indicator of impairment such that an impairment
assessment of the non-current assets allocated to the Photonics and
Wireless CGU's has been performed.
The recoverable amount of the
Photonics and Wireless CGU's have been determined based on value in
use calculations, using cash flow projections for a five-year
period plus a terminal value based upon a long-term growth rate of
2% in line with The Bank of England's monetary policy 2% inflation
target.
Value in use calculations are
based on the Group's latest 2024 and 2025 forecast and latest 2026
to H1 2029 projections which have been adjusted to exclude the
impact of expansionary capital expenditure and certain linked
earnings and cash flows. The value in use calculations incorporate
cashflows associated with the group's diversification into
high-growth GaN power markets. Revenue assumptions in year 1
reflect a gradual improvement in market dynamics and customer
demand, aligned with the low end of current analyst ranges ahead of
an expected full market recovery in year 2 where revenue is aligned
with the higher high end of current analyst ranges. Revenue
assumptions in the adjusted cash flow projections for years 3 to 5
have typically been extrapolated from year 2 using business segment
growth rates that take account of industry trends and external
market research, with incremental customer and market share wins
overlaid on top of market growth assumptions.
The calculation of the recoverable
amount of the CGU in the value in use calculation is highly
sensitive to small changes in the following key assumptions applied
in the 2024 and 2025 cash flow forecast:
|
Year 1
%
|
Year 2
%
|
Year 3
%
|
Year 4
%
|
Year 5
%
|
5 Year
CAGR
%
|
Risk adjusted discount
rate
|
18.1%
|
18.1%
|
18.1%
|
18.1%
|
18.1%
|
N/A
|
Photonics revenue growth
rate
|
Latest
2024 and 2025 forecast
|
Latest
2024 and 2025 forecast
|
5.8%
|
5.0%
|
7.0%
|
18.6%
|
Wireless revenue growth
rate
|
Latest
2024 and 2025 forecast
|
Latest
2024 and 2025 forecast
|
9.3%
|
12.8%
|
6.0%
|
9.4%
|
Year 1 represents H2 2024 and H1 2025, year 2 represents H2
2025 and H1 2026, year 3 represents H2 2026 and H1 2027, year 4
represents H2 2027 and H1 2028, year 5 represents H2 2028 and H1
2029.
Wireless CGU
The recoverable amount of the
Wireless CGU of £106,237,000, determined based on value in use
calculations is greater than the carrying amount (£101,742,000) of
the associated intangible assets, property, plant and equipment and
right of use assets allocated to the CGU such that no impairment of
Wireless CGU assets has been identified.
The Group has carried out a
sensitivity analysis on the impairment test for the Wireless CGU,
using various reasonably plausible scenarios focused on changes in
business segment growth rates, direct wafer product margins and
changes in the discount rate applied in the value in use
calculations.
· Growth
rates in the value in use calculations take account of continuing
market demand for compound semiconductors and associated technology
advancement, driven by macro trends of 5G and connected devices
where 5G network infrastructure and 5G mobile handsets are being
enabled by next generation wireless compound semiconductor
material. If the aggregated compound annual revenue growth rate
used in the value in use calculations to determine the recoverable
amount was to decrease by 1.0%, the magnitude of the adverse impact
on the recoverable amount of Wireless CGU non-current assets would
be £17,993,000.
· If
direct wafer product margins for all products used in the value in
use calculations to determine the recoverable amount were reduced
by 1.0%, the magnitude of the adverse impact on the Wireless CGU
impairment would be £18,321,000.
· If the
discount rate used in the value in use calculations to determine
the recoverable amount was to increase by 0.5%, the magnitude of
the adverse impact on the recoverable amount of Wireless CGU
non-current assets would be £3,775,000.
Photonics CGU
The recoverable amount of the
Photonics CGU of £160,715,000, determined based on value in use
calculations is greater than the carrying amount (£115,448,000) of
the associated intangible assets, property, plant and equipment and
right of use assets allocated to the CGU such that no impairment of
Photonics CGU assets has been identified.
The Group has carried out a
sensitivity analysis on the impairment test for the Photonics CGU,
using various reasonably plausible scenarios focused on changes in
business segment growth rates, direct wafer product margins and
changes in the discount rate applied in the value in use
calculations.
· Growth
rates in the value in use calculations take account of continuing
market demand for compound semiconductors and associated technology
advancement, driven by macro trends of 5G and connected devices,
and the increasing proliferation of 3D and advanced sensing end
user applications that require enabling compound semiconductor
material. If the aggregated compound annual revenue growth rate
used in the value in use calculations to determine the recoverable
amount was to decrease by 1.0%, the magnitude of the adverse impact
on the recoverable amount of Photonics CGU non-current assets would
be £26,503,000.
· If
direct wafer product margins for all products used in the value in
use calculations to determine the recoverable amount were reduced
by 1.0%, the magnitude of the adverse impact on the Photonics CGU
impairment would be £14,556,000.
· If the
discount rate used in the value in use calculations to determine
the recoverable amount was to increase by 0.5%, the magnitude of
the adverse impact on the recoverable amount of Photonics CGU
non-current assets would be £5,743,000.
5. MATERIAL ACCOUNTING
POLICIES
The accounting policies applied in
these interim financial statements are the same as those applied in
the Group's consolidated financial statements as at and for the
year ended 31 December 2023. A number of new standards are
effective from 1 January 2024 but they do not have a material
effect on the Group's financial statements.
Recent accounting developments and
the policy for recognising and measuring income taxes in the
interim period are described below.
5.1 Recent
accounting developments
In preparing the interim financial
statements, the Group has adopted the following Standards,
amendments and interpretations, which are effective for 2024 and
will be adopted in the financial statements for the year ended 31
December 2024:
· Amendment to IAS 1 'Presentation of Financial Statements' on
classification of liabilities which is intended to clarify that
liabilities are classified as either current or non-current
depending upon the rights that exist at the end of the reporting
period. The amendment also requires disclosure of information for
non-current liabilities that are subject to future covenants
relating to the risk that the liability could become repayable
within 12 months.
· Amendment to IAS 7 'Statement of Cash Flows' and IFRS 7
'Financial Instruments: Disclosures' related to the disclosure and
transparency of supplier finance arrangements.
· Amendment to IAS 12 'Income taxes' which provides temporary
mandatory relief from deferred tax accounting for top up tax and
disclosure of new information to compensate for the potential loss
of information arising from the mandatory relief.
· Amendment to IFRS 16 'Leases' which confirms the initial and
subsequent recognition principles for variable lease payments as a
liability in a sale and leaseback transaction
The adoption of these standards and
amendments has not had a material impact on the interim financial
statements.
5.2
Income tax expense
Income tax expense is recognised at
an amount determined by multiplying the loss before tax for the
interim reporting period by management's best estimate of the
weighted-average annual income tax rate expected for the full
financial year, adjusted for the tax effect of certain items
recognised in full in the interim period. As such, the effective
tax rate in the interim financial statements may differ from
management's estimate of the effective tax rate for the annual
financial statements.
6. PRINCIPAL RISKS AND
UNCERTAINTIES
The principal risks and
uncertainties affecting the Group are set out in the Strategic
Report in the 2023 Annual report and financial statements and
remain unchanged at 30 June 2024.The principal risks and
uncertainties include:
· Health, safety, security and environment as the Group
operates a number of manufacturing sites which utilise potentially
harmful gases, materials and equipment
· Availability of sufficient capital and cash liquidity as the
group has been exposed to the semiconductor industry downturn
through late 2022, 20283 and into 2024 which has resulted in
financial losses
· Climate change and the risks relating to supply chain and
business disruption arising from extreme weather events and risks
arising from the failure to meet climate reporting obligations and
increased energy costs
· Loss
of key people
· International trade compliance and the risks associated with
non-compliance with complex international export control
laws
· Intellectual property and the risks associated with either
IQE infringing the intellectual property rights of a third party or
a third party infringing on IQE's intellectual property
rights
· Information technology risks including cyber-attacks, ransom
ware and/or viruses and risks associated with legacy system failure
or cessation
· Business environment, including customer demand and input
cost risks
7. SEGMENTAL
INFORMATION
Revenue
|
6 Months to 30 June
2024
Unaudited
£'000
|
6 Months to 30 June
2023
Unaudited
£'000
|
12 Months to 31 Dec
2023
Audited
£'000
|
|
|
|
|
Wireless
|
38,779
|
22,438
|
53,877
|
Photonics
|
26,765
|
28,012
|
59,098
|
CMOS++
|
474
|
1,566
|
2,277
|
|
|
|
|
Revenue
|
66,018
|
52,016
|
115,252
|
|
|
|
|
Adjusted operating loss
|
|
|
|
|
|
|
|
Wireless
|
4,981
|
(2,978)
|
4,638
|
Photonics
|
(4,338)
|
(6,354)
|
(9,988)
|
CMOS++
|
(964)
|
(932)
|
(2,269)
|
Central corporate costs
|
(6,886)
|
(7,195)
|
(12,580)
|
|
|
|
|
Adjusted operating loss
|
(7,207)
|
(17,459)
|
(20,199)
|
|
|
|
|
Adjusted items
|
|
|
|
|
|
|
|
Wireless
|
(986)
|
(284)
|
(1,004)
|
Photonics
|
(3,157)
|
(825)
|
(2,445)
|
CMOS++
|
(79)
|
(15)
|
(45)
|
Central corporate costs
|
(709)
|
(1,051)
|
(2,086)
|
|
|
|
|
Operating loss
|
(12,138)
|
(19,634)
|
(25,779)
|
|
|
|
|
Finance costs
|
(1,765)
|
(1,832)
|
(3,032)
|
|
|
|
|
Loss before tax
|
(13,903)
|
(21,466)
|
(28,811)
|
8. ADJUSTED PERFORMANCE
MEASURES
The Group's results report certain
financial measures after a number of adjusted items that are not
defined or recognised under IFRS including, adjusted earnings
before interest, tax, depreciation and amortisation, adjusted
operating loss, adjusted loss before income tax and adjusted losses
per share. The Directors believe that the adjusted performance
measures provide a useful comparison of business trends and
performance and allow management and other stakeholders to better
compare the performance of the Group between the current and prior
year, excluding the effects of certain non-cash charges,
non-operational items and significant infrequent items that would
distort period on period comparability. The Group uses these
adjusted performance measures for internal planning, budgeting,
reporting and assessment of the performance of the business. The
tables below show the adjustments made to arrive at the adjusted
performance measures and the impact on the Group's reported
financial performance.
|
Adjusted
|
Adjusted
|
6 months to 30 Jun
2024
Reported
|
Adjusted
|
Adjusted
|
6 months to 30 Jun
2023
Reported
|
Adjusted
|
Adjusted
|
2023
Reported
|
£'000s
|
Results
|
Items
|
Results
|
Results
|
Items
|
Results
|
Results
|
Items
|
Results
|
Revenue
|
66,018
|
-
|
66,018
|
52,016
|
-
|
52,016
|
115,252
|
-
|
115,252
|
Cost of sales
|
(60,316)
|
(710)
|
(61,026)
|
(56,088)
|
(153)
|
(56,241)
|
(111,244)
|
(1,680)
|
(112,924)
|
Gross profit/(loss)
|
5,702
|
(710)
|
4,992
|
(4,072)
|
(153)
|
(4,225)
|
4,008
|
(1,680)
|
2,328
|
Other gains
|
-
|
-
|
-
|
640
|
-
|
640
|
-
|
-
|
-
|
SG&A
|
(13,229)
|
(3,072)
|
(16,301)
|
(14,382)
|
(2,022)
|
(16,404)
|
(26,167)
|
(6,319)
|
(32,486)
|
Impairment (loss)/reversal of
receivables
|
(31)
|
-
|
(31)
|
355
|
-
|
355
|
1,808
|
-
|
1,808
|
Gains on acquisitions
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
2,419
|
2,419
|
Profit/(loss) on disposal of
PPE
|
55
|
(1,149)
|
(1,094)
|
-
|
-
|
-
|
152
|
-
|
152
|
Gain on remeasurement of right of
use asset
|
296
|
-
|
296
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating loss
|
(7,207)
|
(4,931)
|
(12,138)
|
(17,459)
|
(2,175)
|
(19,634)
|
(20,199)
|
(5,580)
|
(25,779)
|
Finance costs
|
(1,765)
|
-
|
(1,765)
|
(1,832)
|
-
|
(1,832)
|
(3,032)
|
-
|
(3,032)
|
Loss before tax
|
(8,972)
|
(4,931)
|
(13,903)
|
(19,291)
|
(2,175)
|
(21,466)
|
(23,231)
|
(5,580)
|
(28,811)
|
Taxation
|
(1,168)
|
-
|
(1,168)
|
141
|
-
|
141
|
(759)
|
192
|
(567)
|
Loss for the period
|
(10,140)
|
(4,931)
|
(15,071)
|
(19,150)
|
(2,175)
|
(21,325)
|
(23,990)
|
(5,388)
|
(29,378)
|
|
Pre-tax
|
Tax
|
6 months to 30 Jun
2024
Reported
|
Pre-tax
|
Tax
|
6 months to 30 Jun
2023
Reported
|
Pre-tax
|
Tax
|
2023
Reported
|
£'000s
|
Adjustment
|
Impact
|
Results
|
Adjustment
|
Impact
|
Results
|
Adjustment
|
Impact
|
Results
|
Share based payments
|
(2,129)
|
-
|
(2,129)
|
(460)
|
-
|
(460)
|
(2,520)
|
192
|
(2,328)
|
Share based payments - CEO
recruitment
|
(38)
|
-
|
(38)
|
(6)
|
-
|
(6)
|
(45)
|
-
|
(45)
|
Share based payments - CFO
recruitment
|
(67)
|
-
|
(67)
|
-
|
-
|
-
|
-
|
-
|
-
|
CEO recruitment
|
(153)
|
-
|
(153)
|
(147)
|
-
|
(147)
|
(300)
|
-
|
(300)
|
CFO recruitment
|
-
|
-
|
-
|
(326)
|
-
|
(326)
|
(454)
|
-
|
(454)
|
Gain on deemed disposal of
CSC
|
-
|
-
|
-
|
-
|
-
|
-
|
2,419
|
-
|
2,419
|
Restructuring
|
(1,305)
|
-
|
(1,305)
|
(1,236)
|
-
|
(1,236)
|
(4,680)
|
-
|
(4,680)
|
Restructuring - loss on disposal of
PPE
|
(1,149)
|
-
|
(1,149)
|
-
|
-
|
-
|
-
|
-
|
-
|
Restructuring - impairment of
PPE
|
(90)
|
-
|
(90)
|
-
|
-
|
-
|
-
|
-
|
-
|
Total
|
(4,931)
|
-
|
(4,931)
|
(2,175)
|
-
|
(2,175)
|
(5,580)
|
192
|
(5,388)
|
The nature of the adjusted items
is as follows:
Current period:
· Share
based payments - The charge recorded in accordance with IFRS 2
'share based payment' of which £710,000 (H1 2023: £153,000 2023:
£840,000) has been classified within cost of sales in gross profit
and £1,419,000 (H1 2023: £307,000, 2023: £1,680,000) in selling,
general and administrative expenses within operating loss. Cash
costs defrayed in the period total £117,000 (H1 2023: £nil 2023:
£nil) in respect of employer social security contributions relating
to unapproved employee share options. Share based payments which
arise each financial year are classified as an APM due to the
non-cash charge being partially outside of the Group's control as
it is based on factors such as share price volatility and interest
rates which may be unrelated to the performance of the Group during
the period in which the expense occurred.
· Chief
Executive Officer recruitment - The Chief Executive Officer's
starting bonus of £1,000,000, of which £200,000 relates to a
share-based payment award and £800,000 relates to a cash award, is
payable over the first three years of employment. The charge of
£38,000 (H1 2023: £6,000, 2023: £45,000) relates to the share
element of the new starter award and the charge of £153,000 (H1
2023: £153,000, 2023: £345,000) relates to costs associated with
the cash element of the award. Cash costs defrayed in the period
total £nil (H1 2023: £463,000, 2023: £463,000).
· Chief
Finance Officer recruitment - The charge of £67,000 (H1 2023: £nil,
2023: £nil) relates to the share-based payment element of the new
Chief Finance Officer's starter award. No other recruitment or
severance costs relating to the change in Chief Finance Officer
have been incurred in the current period with prior year costs
relating to external recruitment costs in relation to newly
appointed Chief Finance Officer and settlement costs and legal fees
in relation to the former Chief Financial Officer (H1 2023:
£326,000, 2023: £454,000). Cash costs defrayed in the period total
£nil (H1 2023: £280,000, 2023: £454,000).
· Restructuring - The charge of £2,544,000 (H1 2023:
£1,236,000, 2023: £4,680,000) relates to the closure of the Group's manufacturing facility in Pennsylvania,
the strategic repurposing of the Group's silicon site in the UK and
final costs and expenses related to the closure of the Group's
Singapore operations:
- Restructuring charges of £2,496,000 (H1 2023: £450,000, 2023:
£3,390,000) consist of employee related costs of £135,000 (H1 2023:
£450,000, 2023: £1,789,000), site decommissioning costs of
£1,101,000 (H1 2023: £nil, 2023: £1,601,000) and loss on disposal
and impairment of PPE of £1,260,000 (H1 2023: £nil, 2023: £nil)
relating to the announced closure of the Group's manufacturing
facility in Pennsylvania, USA in 2024. The charge was classified as
selling, general and administrative expenses and loss on disposal
of PPE within operating loss. As at 30 June 2024, cumulative
restructuring charges of £7,842,000 (H1 2023 £2,096,000, 2023:
£5,346,000) have been incurred. Cash costs totalling £7,878,000 (H1
2023: £1,136,000, 2023: £4,037,000) has been incurred to date with
£3,841,000 (H1 2023: 186,000, 2023: £3,087,000) defrayed in the
current period.
- Restructuring charges of £67,000 (H1 2023: £nil, 2023: £nil)
consist of employee related costs of £88,000 (H1 2023: £nil, 2023:
£nil) and profit on disposal of PPE of £21,000 (H1 2023: £nil,
2023: £nil), in relation to the strategic repurposing of the
silicon site in the UK. The charge was classified as selling,
general and administrative expenses and loss on disposal of PPE
within operating loss. Cash costs defrayed in the period total
£88,000 (H1 2023: £nil, 2023: £nil). Proceeds on disposal of PPE in
the period total £851,000 (H1 2023: £nil, 2023: £nil).
- Restructuring charges of £nil (H1 2023: £786,000, FY23:
£1,290,000) relate to labour costs associated with a group wide
restructuring programme and associated employee redundancies
(excluding costs relating to the closure of the group's
manufacturing facility in Pennsylvania). The charge was classified
as selling, general and administrative expenses within operating
loss. Cash costs defrayed in the period total £nil (H1 2023:
£786,000 2023: £1,290,000).
- Restructuring credit of £19,000 (H1 2023: £nil, 2023: £nil)
relating to the voluntary liquidation of the Group's Singapore
subsidiaries, where manufacturing operations ceased in June 2022.
The credit was classified as selling, general and administrative
expenses within operating loss. Cash credits in the period total
(£19,000) (H1 2023: £nil, 2023: £nil).
Prior periods
· Gain
on acquisitions of £nil (H1 2023: £nil, 2023: £2,419,000) relates
to the gain recognised on acquisition of the remaining shares in
the Group's joint venture, CSC, increasing its shareholding to
100%. Cash costs defrayed in the period relating to deferred
consideration in respect of the acquisition total £128,000 (H1
2023: £nil, 2023: £nil).
The cash impact of adjusted items
in the consolidated cash flow statement represents costs associated
with employer social security contributions relating to unapproved
employee share options of £117,000 (H1 2023: £nil 2023: £nil), the
recruitment of the group's Chief Executive Officer of £nil (H1
2023: £463,000, 2023: £463,000), the recruitment and severance of
the group's new and former Chief Finance Officer of £nil (H1 2023:
£280,000, 2023: £454,000), payment of employee and site related
decommissioning costs associated with the closure of the Group's
site in Pennsylvania of £3,841,000 (H1 2023: £186,000, 2023:
£3,087,000), payment of employee related costs associated with the
repurposing of the silicon site in the UK of £88,000 (H1 2023:
£nil, 2023: £nil), final net cash receipts of £19,000 (H1 2023:
£nil, 2023: £nil) relating to the voluntary liquidation of the
Group's Singapore subsidiaries following closure of the site in
2022, onerous contract royalty payments related to the Group's
cREO™ technology of £394,000 (H1 2023: £41,000, 2023: £256,000) and
payment of employee related costs associated with labour cost
reductions within the Group of £nil (H1 2023: £786,000, 2023:
£1,290,000).
Adjusted EBITDA (adjusted earnings
before interest, tax, depreciation and amortisation) has been
calculated as follows:
(All figures £'000s)
|
6 months to
30 June
2024
Unaudited
|
6 months to
30 June
2023
Unaudited
|
12 months
to
31 Dec 2023
Audited
|
Loss attributable to equity shareholders
|
(15,071)
|
(21,325)
|
(29,378)
|
Finance costs
|
1,765
|
1,832
|
3,032
|
Tax
|
1,168
|
(141)
|
567
|
Depreciation of property, plant and
equipment
|
8,796
|
6,073
|
13,186
|
Depreciation of right of use
assets
|
1,791
|
1,898
|
3,790
|
Impairment of right of use
asset
|
32
|
-
|
-
|
Amortisation of intangible fixed
assets
|
3,546
|
3,750
|
7,688
|
Profit on disposal of PPE and
intangibles*
|
(55)
|
-
|
(152)
|
Gain on remeasurement
|
(296)
|
-
|
-
|
Adjusted Items
|
4,931
|
2,175
|
5,580
|
Share based payments
|
2,129
|
460
|
2,520
|
Share based payments - CEO &
CFO recruitment
|
105
|
6
|
45
|
CEO recruitment
|
153
|
147
|
300
|
CFO recruitment &
severance
|
-
|
326
|
454
|
Gain on deemed disposal of
JV
|
-
|
-
|
(2,419)
|
Restructuring
|
1,305
|
1,236
|
4,680
|
Restructuring - loss on disposal of
PPE
|
1,149
|
-
|
-
|
Restructuring - impairment of
PPE
|
90
|
-
|
-
|
Adjusted EBITDA
|
6,607
|
(5,738)
|
4,313
|
Share based payments
|
(2,129)
|
(460)
|
(2,520)
|
Share based payments - CEO &
CFO recruitment
|
(105)
|
(6)
|
(45)
|
CEO recruitment
|
(153)
|
(147)
|
(300)
|
CFO recruitment &
severance
|
-
|
(326)
|
(454)
|
Gain on deemed disposal of
JV
|
-
|
-
|
2,419
|
Restructuring
|
(1,305)
|
(1,236)
|
(4,680)
|
EBITDA
|
2,915
|
(7,913)
|
(1,267)
|
* Excludes the adjustment
'Restructuring - loss on disposal of PPE' which is separately
disclosed as part of the groups adjusted items
9. TAXATION
The Group's consolidated effective
tax rate for the six months ended 30 June 2024 was 8.4%
(H1 2023: 0.7%, 2023: 2.0%). The
effective tax rate differs from the theoretical amount that would
arise from applying the standard corporation tax in the UK of 25.0%
(H1 2023: 19.0%, 2023: 23.5%) principally due to
non-recognition of current year tax losses in the UK and
USA.
10. LOSS PER SHARE
(All figures £'000s)
|
6 months to
30 June
2024
Unaudited
|
6 months to
30 June
2023
Unaudited
|
12 months
to
31 Dec 2023
Audited
|
Loss attributable to ordinary
shareholders
|
(15,071)
|
(21,325)
|
(29,378)
|
Adjustments to loss after tax
(note 8)
|
4,931
|
2,175
|
5,388
|
Adjusted loss attributable to ordinary
shareholders
|
(10,140)
|
(19,150)
|
(23,990)
|
|
|
|
|
Number of shares:
|
|
|
|
Weighted average number of
ordinary shares
|
961,679,720
|
830,940,409
|
896,744,318
|
Dilutive share options
|
8,031,368
|
4,621,705
|
10,155,464
|
|
969,711,088
|
835,562,114
|
906,899,782
|
Basic loss per share
|
(1.57p)
|
(2.57p)
|
(3.28p)
|
|
|
|
Adjusted loss per share
|
(1.05p)
|
(2.30p)
|
(2.68p)
|
|
|
|
|
|
|
|
|
|
|
Diluted loss per share
|
(1.57p)
|
(2.57p)
|
(3.28p)
|
|
|
|
Adjusted diluted loss per
share
|
(1.05p)
|
(2.30p)
|
(2.68p)
|
|
|
|
Basic loss per share is calculated
by dividing the loss attributable to ordinary shareholders by the
weighted average number of ordinary shares during the
period.
Diluted loss per share is
calculated by dividing the loss attributable to ordinary
shareholders by the weighted average number of shares and 'in the
money' share options in issue. Share options are classified as 'in
the money' if their exercise price is lower than the average share
price for the period. As required by IAS 33, this calculation
assumes that the proceeds receivable from the exercise of 'in the
money' options would be used to purchase shares in the open market
in order to reduce the number of new shares that would need to be
issued.
11. CASH GENERATED FROM OPERATIONS
(All figures £'000s)
|
6 months to
30 June
2024
Unaudited
|
6 months to
30 June
2023
Unaudited
|
12 months
to
31 Dec 2023
Audited
|
Loss before tax
|
(13,903)
|
(21,466)
|
(28,811)
|
Finance costs
|
1,765
|
1,832
|
3,032
|
Depreciation of property, plant
and equipment
|
8,796
|
6,073
|
13,186
|
Impairment of property, plant and
equipment
|
90
|
-
|
-
|
Depreciation of right of use
assets
|
1,791
|
1,898
|
3,790
|
Impairment of right of use
assets
|
32
|
-
|
-
|
Amortisation of intangible
assets
|
3,546
|
3,750
|
7,688
|
Inventory provision write
downs
|
469
|
760
|
522
|
Non-cash movement on trade
receivable expected credit losses
|
31
|
(355)
|
(1,808)
|
Non-cash provision
movements
|
143
|
404
|
1,599
|
Fair value gain on derivative
financial instruments
|
-
|
(640)
|
-
|
Gain on deemed disposal of
JV
|
-
|
-
|
(2,419)
|
Loss/(profit) on disposal of
property, plant and equipment
|
1,094
|
-
|
(152)
|
Gain on remeasurement of right of
use asset
|
(296)
|
-
|
-
|
Share based payments
|
2,234
|
466
|
2,565
|
Cash inflow from operations before changes in working
capital
|
5,792
|
(7,278)
|
(808)
|
(Increase)/decrease in
inventories
|
(1,345)
|
5,946
|
7,503
|
(Increase)/decrease in trade and
other receivables
|
(9,315)
|
7,185
|
6,601
|
Increase/(decrease) in trade and
other payables
|
4,566
|
(3,043)
|
(1,760)
|
Decrease in provisions
|
(2,330)
|
(378)
|
(1,462)
|
Cash inflow from operations
|
(2,632)
|
2,432
|
10,074
|
12. ANALYSIS OF NET DEBT
(All figures £'000s)
|
6 months to
30 June
2024
Unaudited
|
6 months to
30 June
2023
Unaudited
|
12 months
to
31 Dec 2023
Audited
|
|
|
|
|
Bank borrowings due after one
year
|
(23,220)
|
(845)
|
(3,692)
|
Bank borrowings due within one
year
|
(1,569)
|
(6,123)
|
(4,153)
|
Lease liabilities due after one
year
|
(44,493)
|
(42,826)
|
(40,435)
|
Lease liabilities due within one
year
|
(7,329)
|
(7,140)
|
(5,865)
|
Total borrowings
|
(76,611)
|
(56,934)
|
(54,145)
|
Fair value of derivative financial
instruments
|
-
|
259
|
-
|
Cash and cash
equivalents
|
7,810
|
12,314
|
5,617
|
Net debt
|
(68,801)
|
(44,361)
|
(48,528)
|
On 17 May 2023, the Company
refinanced its £27,300,000 ($35,000,000) multi-currency revolving
credit facility, provided by HSBC Bank plc. The facility is secured
on the assets of IQE plc and its subsidiary companies with a
committed term to 1 May 2026. Interest on the facility is payable
at a margin of between 2.50 and 3.50 per cent per annum over SONIA
on any drawn balances and the facility is subject to quarterly
leverage and Interest cover
covenants tests. The facility was
£23,220,000 (H1 2023 £nil, 2023: £3,937,000) utilised at 30 June
2024.
On 29 August 2019, the Company
agreed a new £30,000,000 asset finance facility, provided by HSBC
Bank plc that is secured over various plant and machinery assets.
The facility has a five-year term and an interest rate margin of
1.65% per annum over base rate on any drawn balances.
The Group's bank facilities
provided by HSBC Bank plc are subject to certain leverage and
interest cover financial covenants. The Group has complied with all
the financial covenants of its borrowing facilities during 2024 and
2023.
Bank borrowings relate to amounts
drawn down on the Group's multi-currency revolving credit and asset
finance facilities.
Cash and cash equivalents comprise
balances held in instant access bank accounts and other short-term
deposits with a maturity of less than 3 months.
13. SHARE CAPITAL
Number of shares
|
6 months to
30 June
2024
Unaudited
|
6 months to
30 June
2023
Unaudited
|
12 months
to
31 Dec 2023
Audited
|
|
|
|
|
As at 1 January
|
961,518,692
|
804,841,965
|
804,841,965
|
Employee share schemes
|
5,114,245
|
1,052,260
|
1,183,997
|
Placing
|
-
|
150,000,000
|
150,000,000
|
Retail Offer
|
-
|
5,492,730
|
5,492,730
|
As at 30 June / 31 December
|
966,632,937
|
961,386,955
|
961,518,692
|
(All figures £'000s)
|
6 months to
30 June
2024
Unaudited
|
6 months to
30 June
2023
Unaudited
|
12 months
to
31 Dec 2023
Audited
|
|
|
|
|
As at 1 January
|
9,615
|
8,048
|
8,048
|
Employee share schemes
|
51
|
11
|
12
|
Placing
|
-
|
1,500
|
1,500
|
Retail Offer
|
-
|
55
|
55
|
As at 30 June / 31 December
|
9,666
|
9,614
|
9,615
|
On 17 May 2023, IQE plc raised
funds by way of a Placing and a Retail Offer to all existing
shareholders. In each case these were offered at an issue price of
20 pence per share (the 'Issue Price'). The Placing utilised a
cashbox structure and therefore the premium on the ordinary shares
and associated costs, in accordance with section 612 of the
Companies Act 2006, were initially recognised within the merger
reserve (incorporated within 'Other reserves'). The investment in
the newly incorporated subsidiary utilised within the cashbox
structure was dissolved in the year ended 31 December 2023 and the
merger reserve was subsequently transferred into retained earnings
as it was determined to be distributable in accordance with the
Companies Act 2006. The Placing and Retail Offer raised net funds
of £29,708,000 from the issue of 155,492,730 ordinary
shares.
14. COMMITMENTS
The Group had capital commitments
at 30 June 2024 of £452,000 (H1 2023: £12,197,000, 2023:
£553,000).
RESPONSIBILITY STATEMENT
We confirm that to the best of our
knowledge:
· the
condensed set of financial statements has been prepared in
accordance with IAS 34 Interim Financial Reporting as adopted for
use in the UK;
· the
interim management report includes a fair review of the information
required by:
(a) DTR 4.2.7R of the Disclosure
Guidance and Transparency Rules, being an indication of important
events that have occurred during the first six months of the
financial year and their impact on the condensed set of financial
statements; and a description of the principal risks and
uncertainties for the remaining six months of the year;
and
(b) DTR 4.2.8R of the Disclosure
Guidance and Transparency Rules, being related party transactions
that have taken place in the first six months of the current
financial year and that have materially affected the financial
position or performance of the entity during that period; and any
changes in the related party transactions described in the last
annual report that could do so.
Americo Lemos
Chief Executive Officer, IQE
plc.
9 September 2024
|
Jutta Meier
Chief Financial Officer, IQE
plc.
9 September 2024
|